Biliary Epithelial Apoptosis, Autophagy, and Senescence in Primary Biliary Cirrhosis by Sasaki, Motoko & Nakanuma, Yasuni
Hindawi Publishing Corporation
Hepatitis Research and Treatment
Volume 2010, Article ID 205128, 10 pages
doi:10.1155/2010/205128
Review Article
BiliaryEpithelialApoptosis, Autophagy, andSenescencein
Primary BiliaryCirrhosis
Motoko Sasaki andYasuniNakanuma
Department of Human Pathology, Kanazawa University Graduate School of Medicine, Kanazawa 920-8640, Japan
Correspondence should be addressed to Motoko Sasaki, m8sasaki@med.kanazawa-u.ac.jp
Received 28 August 2010; Accepted 5 October 2010
Academic Editor: Annarosa Floreani
Copyright © 2010 M. Sasaki and Y. Nakanuma.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease characterized serologically by the high prevalence of anti-
mitochondrial autoantibodies (AMAs) and histologically by the cholangitis of small bile ducts, eventually followed by extensive
loss of the small bile duct. An autoimmune pathogenesis is suggested by clinical and experimental studies, but there remain issues
regarding the etiology, the signiﬁcance of AMAs in the pathogenesis of bile duct lesions, and so on. The unique properties of
apoptosis in biliary epithelial cells (BECs), in which there is exposure of autoantigen to the eﬀectors of the immune system, are
proposed to be a cause of bile duct lesions in PBC. Recent progress disclosed that cellular senescence and autophagy are involved
in bile duct lesions in PBC. Senescent BECs may modulate the periductal microenvironment by expressing senescence-associated
secretory phenotypes, including various chemokines, and contribute to the pathogenesis of bile duct lesions in PBC.
1.Introduction
Primary biliary cirrhosis (PBC) is a chronic, progressive
cholestatic liver disease in which autoimmune pathogenesis
is suggested [1–4]. It usually aﬀects middle-aged women
[1, 5] and often leads to liver failure and liver transplantation
[2, 3]. PBC is characterized histologically as cholangitis
of small bile ducts (chronic nonsuppurative destructive
cholangitis; CNSDC) eventually followed by the extensive
loss of small bile ducts [2, 3, 6]. Biliary epithelial cells
(BECs) are thought to be the major target of injury in
PBC. PBC is serologically characterized by the presence
of increased levels of immunoglobulin M (IgM), a high
titer of serum antimitochondrial autoantibodies (AMAs),
and, in some patients, PBC-speciﬁc antinuclear antibodies
(ANAs) [1, 2, 7–10]. AMAs are present in about 95% of
PBC cases, with disease speciﬁcity close to 100%, and are
therefore considered the serological hallmark of the disease.
The major epitope site for both the B-cell and CD4 and
CD8 T-cell response is an inner lipoyl domain of the E2
component of pyruvate dehydrogenase (PDC-E2) [10–13].
There have been many studies on the immunopatho-
logical features [10–13], genetic factors [14–17], and envi-
ronmental factors [5, 18–20], including infectious agents
and xenobiotics. The most accepted hypothesis states that
PBC results from an environmental insult on a genetically
susceptible background. In this scenario, adaptive immu-
nity, both humoral and cellular (CD4 and CD8 T cells),
and innate immunity have been proposed as coplayers
in immune-mediated liver damage; however, there remain
many mysteries in the etiology and pathogenesis of PBC;
in particular, the signiﬁcance of AMAs and autoantigen-
speciﬁc T-cell response in the pathogenesis of bile duct
lesions remains unknown. One hypothesis proposed that
a BEC-speciﬁc autoimmune reaction, possibly causing bile
duct lesions, is a unique property of apoptosis in bil-
iary epithelial cells (BECs), in which there is exposure
of autoantigen to the eﬀectors of the immune system
[4, 21–23]. In addition, our recent studies disclosed that
cellular senescence and autophagy are involved in the bile
duct lesion in PBC [24–28]. These two novel cellular
processes may be related to the immunopathology of BECs
together with AMAs in PBC. At least, it is likely that
senescent BECs modulate the periductal microenvironment
by expressing senescence-associated secretory phenotypes
(SASPs) including various chemokines and contribute to the
pathogenesis of bile duct lesions in PBC [29]. In this paper,
we will focus on studies addressing the features of BECs2 Hepatitis Research and Treatment
in PBC and its possible involvement in the progression of
diseases.
2.AutoantibodiesinPBC
2.1. AMAs. AMAs are present in about 95% of PBC cases,
with disease speciﬁcity close to 100%, and are therefore con-
sidered the serological hallmark of the disease. The targets of
AMAsaremembersofthe2-oxoaciddehydrogenasecomplex
(2-OADC), including the E2 subunit of pyruvate dehydroge-
nase complex (PDC-E2), the E2 subunit of branched chain
2-oxoacid dehydrogenase complex (BCOADC-E2), the E2
subunit of 2-oxoglutarate dehydrogenase complex (OGDC-
E2), and dihydrolipoamide dehydrogenase binding protein
(E3BP), which is a component of the PDC complex [1, 7–
10]. The most common AMAs reactivity is with PDC-
E2; whereas some patients have AMAs reacting with PDC-
E2 alone, most have reactivity also with OGDC-E2 or
BCOADC-E2; reactivity to BCOADC-E2 or OGDC-E2 alone
is less common. It is located in the mitochondrial matrix,
associated with the inner membrane, and catalyzes the
oxidative decarboxylation of various α- ketoacid substrates.
The major epitope site of both B-cell and CD4 and CD8
T-cell responses is the inner lipoyl domain of the E2
component of pyruvate dehydrogenase (PDC-E2) [10–13].
These domains contain ETDKA, ETDK(T), and (GlnS)DKA
withlipoicacidcovalentlyboundtotheε groupoflysine(K).
In addition to sera, AMAs, especially the IgA isotype, and the
autoantigens, PDC-E2, OGDC-E2, and BCOADC-E2, were
detected frequently in the bile of patients with PBC [30].
Although AMAs are detected in approximately 95% of
patients, their direct pathogenetic role is still poorly under-
stood. A minor population of patients is AMA-negative, and
these AMA-negative cases manifest similar histological fea-
tures and disease progression [31]. In autoimmune disease,
the reduction of disease-speciﬁc autoantibody titers corre-
lates with disease amelioration; this criterion is not suitable
for PBC, in which there is no correlation between the pattern
or titer of AMAs and the progression or severity of diseases
[4,32]. Furthermore, most autoimmune diseases are respon-
sive to immunosuppressive therapy, while no such agent has
proven eﬀective for PBC [33]. Further, in the autoimmunity
paradigm, experimental immunization with disease-speciﬁc
autoantigens rarely reproduces a model disease.
2.2. ANA. In PBC, there are highly disease-speciﬁc and
antigen-speciﬁc antinuclear activities directed as a variety
of antigens, including centromere, nucleoporins gp210 and
p62, and Sp100 [34–36]. Gp210 is a 210-kd transmembrane
glycoprotein believed to be involved in the attachment of
pore complex constituents in the nuclear membrane. These
antibodies are found in about 25% (between 10% and
40%) of patients with AMA-positive PBC and up to 50%
of those with AMA-negative PBC; the speciﬁcity for PBC,
when detected by immunoblotting, is over 99% [34]. p62
is another nuclear pore glycoprotein speciﬁc to PBC and is
present in about 25% of patients with PBC [35], although
patients with anti-gp210 and p62 appear to be mutually
exclusive.
In contrast to AMAs, there is a signiﬁcant correlation
of disease severity and clinical types with antibodies to
gp210 and centromere [36]. Nakamura et al. reported that
positive anti-gp210 antibodies were a siginiﬁcant risk factor
for the hepatic failure type of progress, whereas positive anti-
centromereantibodieswereasigniﬁcantriskfactorforportal
hypertension-type progression [36]. Histologically, positive
anti-gp210 antibodies were most signiﬁcantly associated
with more severe interface hepatitis and lobular inﬂamma-
tion, whereas positive anti-centromere antibodies were most
signiﬁcantly associated with a more severe ductular reaction
[36]. The pathological role of these antibodies, however, has
been poorly investigated so far, and this clearly warrants
further research.
3.BiliaryEpithelialLesionsinPBC
3.1. Histology of PBC. The bile duct damage characteristic of
early PBC mainly aﬀects the septal and larger interlobular
bile ducts, while the smaller interlobular ducts remain intact
until later. The term chronic nonsuppurative destructive
cholangitis (CNSDC) more accurately describes the initial
lesions in PBC [2, 3, 6, 37]. The epithelium of the aﬀected
ducts becomes irregular and inﬁltrated with lymphocytes.
The basement membrane becomes disrupted, and the duct
may rupture. An inﬂammatory inﬁltrate is seen around or
to one side of the duct. The denser parts of this inﬁltrate
are mainly composed of lymphocytes, which may form
aggregates of follicles with germinal centers. Elsewhere, there
is a mixture of plasma cells, often abundant, eosinophils,
and neutrophils. Granulomas are present in many patients,
although they are not necessarily seen [37]. They take a
variety of forms, ranging from well-deﬁned granulomas, like
those of sarcoidosis or tuberculosis, to small focal collections
of histiocytoid cells.
The aﬀected bile ducts eventually disappear from the liv-
er, and chronic cholestatic features develop gradually. At the
same time, hepatitis activity of varying degrees is frequently
imposed on the liver. Chronic cholangitis activity and
hepatitisactivityinvariouscombinationsmayberesponsible
for progressive hepatocellular damage and ﬁbrosis, and
cirrhosis and hepatic failure ﬁnally develop. We proposed
a new histological staging and grading system of PBC
for comprehensive analysis of the histological progression
of PBC (staging) toward extensive bile duct loss, chronic
cholestasis, and cirrhosis, and also the immune-mediated
necroinﬂammatory activity of small bile ducts and hepato-
cytes [38].
4.Immunopathology ofPBC
Mechanisms involved in the disruption of the biliary epithe-
lium in PBC, especially the association between AMAs and
bile duct damage, remain poorly understood. Several mech-
anisms have been proposed regarding immune-mediated
bile duct damage in PBC, including (1) T-cell-mediated
cytotoxicity and (2) interaction of the IgA class of AMAs
andmitochondrialautoantigensinBECsduringintracellular
transport, resulting in cytotoxicity. In the autoimmuneHepatitis Research and Treatment 3
pathology of PBC, it remains controversial whether BECs
are innocent victims or active participants [4, 39]. BECs
may be active participants rather than innocent victims
in the autoimmune pathology of PBC [4], due to the
anomaly of apoptosis by which a lack of glutathionylation
exposes PDC-E2 in BECs to autoimmune eﬀector agents
[21–23,40].Suchpropertiesmayincludeuniqueprocessesof
apoptosis, mechanisms related to mitochondrial autophagy,
the presence of poly Ig receptors and, especially, in the
case of BECs, a capacity to elicit intense mucosal responses
[41]. In contrast, Shimoda et al. proposed that BECs are
in fact innocent victims of autoimmune injury and that
the adaptive immune response is critical in PBC [39]. They
reported that BECs isolated from PBC patients and controls
express similar levels of Toll-like receptor subtypes, CD40
and HLA-DR [39]. Interestingly, however, BEC-expressed
chemokines elicit enhanced transmigration of PBC liver-
inﬁltrating mononuclear cells compared with controls [39].
5. Altered Features of BECs in PBC
As BEC is thought to be a major target of immune-mediated
attack, a number of studies have focused on the changes
of BECs in PBC in comparison with other hepatobiliary
diseases [4, 37, 42]. Because of the speciﬁcity of interlobular
bile duct damage in PBC patients, it is logical to hypothesize
that this particular segment of bile ducts expresses a speciﬁc
antigenic molecule presented to the immune system. In
addition, the heterogeneity of BECs related to the size of
the bile duct was noted to address the question of why only
small bile ducts, but not large bile ducts, are aﬀected in PBC.
Several studies have reported the altered characteristics of
BECs in PBC. Most of these changes are related to epithelial
damage and suggested to be reactive changes irrespective of
disease [5, 42–47] .T h e r eh a v eb e e nf e wc h a n g e si nB E C st h a t
are truly speciﬁc to PBC. Recently, we have reported that
BECs in damaged small bile ducts show features of cellular
senescence and autophagy in PBC and speculated that the
cellular senescence may be involved in the pathogenesis of
progressive bile duct loss in PBC [24–28].
5.1. Immune Adhesion Molecules. Several studies suggest
that BEC is an antigenically distinct expressing molecule
associated with the immune recognition of targets [42].
These include MHC class II (HLA-DR) and ICAM-1, which
are critical for the interaction with lymphocytes and are
upregulated in PBC [48–50], although these molecules are
commonly induced in liver disease and are not speciﬁc to
PBC. MHC class-II (HLA-DR) was newly expressed during
the intermediate stage of PBC, but early in the disease
HLA-DR expression on BEC is not detected or is present
in only a few ducts [49]. Furthermore, BECs also express
high levels of several adhesion molecules, including ICAM-1
and LFA-3, which are important for mediating adhesion to
lymphocytes [48, 50].
5.2. Inﬂammatory Cytokines and Chemokines
5.2.1. IL-6 and TNF-α. BECs overexpress IL-6 and TNF-α in
PBC and, to a lesser degree, in other hepatobiliary diseases
[47]. TNF receptor and IL-6 receptor were detected on these
damaged bile ducts, suggesting an autocrine eﬀect [47]. The
increased expression of IL-6 and TNF-α could ﬁrst aﬀect the
proliferation, maturation, and regulation of B-cell and T-cell
lineages inﬁltrating around bile ducts [51]. IL-6 promotes
the terminal diﬀerentiation of B cells and immunoglobulin
secretion. TNF-α may induce the expression of adhesion
molecules and various HLA-DR antigens on bile ducts and
may also increase the cytotoxic activities of T cells. IL-6
may be responsible for biliary epithelial proliferation via
autocrine eﬀects [52], and TNF-α may be involved in biliary
epithelial cell damage [53]. TNF-α is also known to disturb
the barrier function of bile ducts, which may lead to the
leakage of toxic substances in bile, a local inﬂammatory
process, and cholangitis [54].
5.2.2. Chemokines. Previous reports, including those from
our group, have reported the upregulation of several
chemokines, that is, CCL2/MCP-1, CX3CL1/fractalkine in
BECs in PBC [29, 55–57]. It is conceivable that BEC-
expressed chemokines participate in the accumulation and
migration of various inﬂammatory cells, forming bile duct
lesions in PBC. Our recent study [29] suggests that some
of these chemokines may belong to senescence-associated
secretory phenotypes (SASP) secreted by senescent BECs, as
will be discussed below.
5.3. MUC Mucins and Trefoil Factors. Mucins and trefoil
factors (TFFs) play a role in the protection of mucosa
forming a mucus barrier. The intrahepatic biliary tree shows
the site-characteristic expression of mucins and TFFs [58,
59]. BECs express physiologically a glycosylated form of
MUC1 detected by anti-EMA antibody in intrahepatic small
bile ducts. MUC4 and MUC5B mucins are also expressed
focally and weakly in BECs in normal small bile ducts.
5.3.1. MUC1. In the normal liver, MUC1 mucin of the
unglycosylated form detected by DF3 is infrequently and
focally expressed in BECs in small bile ducts. In contrast,
MUC1 mucin of the unglycosylated form is frequently
and strongly positive on the luminal surface of BECs in
small bile ducts in PBC and chronic viral hepatitis (CVH)
[60]. In particular, a high level of MUC1 mucin of the
unglycosylated type is expressed in BECs in small bile ducts
involved in CNSDC in PBC and hepatitic bile duct lesion
in CVH [60]. The frequent expression of MUC1 mucin of
the unglycosylated type may therefore be a reactive change to
injuries in BECs [60].
5.3.2. MUC6. MUC6 mucin is focally and weakly expressed
in small bile ducts in normal livers [43]. The expression of
MUC6 mucin is increased in small bile ducts in CVH and,
to a lesser degree, in other hepatobiliary diseases, including
PBC. The extent of MUC6 expression in bile ductules is
in parallel to the degree of active inﬂammation in CVH
[43]; therefore, it is conceivable that MUC6 mucin is up-
regulated in inﬂammatory conditions and may play a role as
ac y t o p r o t e c t i v ea g e n t[ 43].4 Hepatitis Research and Treatment
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Figure 1: Cellular processes: apoptosis, autophagy, and cellular
senescence are distinct cellular response to stress. Autophagy and
apoptosis are induced in response to awide variety of stresses.
There are many purposes for autophagy that include the quality
control of protein and organelle, damage mitigation, and energy
homeostasis. Stressed cells activate autophagy, which prevents
damage and maintains metabolism though lysosomal turnover of
cellular components. Autophagy can facilitate senescence or limit
damage and delay apoptosis to allow recovery of normal cell
function.
5.3.3. TFFs. The intrahepatic biliary tree shows the site-
characteristic expression and induction of TFF1, 2, 3 and
DMBT1, a putative receptor of TFFs. In large bile ducts,
TFF1 and 3 are constitutively expressed and increased in
pathologic bile ducts [45, 61, 62]. In small bile ducts,
TFF2/DMBT1 is induced in damaged ducts, irrespective
of the etiology. For example, the augmented expression of
TFF2/DMBT1 is observed in BECs involved in CNSDC in
PBC and hepatitic bile duct lesions in CVH. The expressions
of TFF1 and 3 are also increased in BECs involved in CNSDC
in PBC [45]. TFF3 expression is regulated by IL-6 via a signal
transducer and activator of the transcription (STAT3) signal-
ing pathway, and TFF3 contributes to BEC migration [63].
6. Cellular ProcessesInvolvedinPBC:
Apoptosis, Autophagy,andCellular
Senescence
Apoptosis, autophagy, and cellular senescence are distinct
cellular responses to stress, correlating with each other
(Figure 1)[ 64]. An appropriate cellular stress response is
critical for maintaining tissue integrity and function and
for preventing diseases [64]. Cells responding to stress with
adaptation, repair, and recovery are diverted into irreversible
cell cycle exit (senescence) or are eliminated through pro-
grammed cell death (apoptosis) [64]. Autophagy, which
literally means “self-eating,” is an evolutionarily conserved
process that results from various cellular stresses such as
nutrient damage and activation of the endoplasmic reticu-
lum stress pathway [65, 66]. Autophagy can enable adapta-
tion to stress through the degradation of cellular proteins
and organelles to suppress damage, maintain metabolism,
and promote cellular viability and ﬁtness [64–67]. These
cell fate decisions are critical to dealing with the emergence
of damaged and potentially dangerous cells that can cause
cancer. Cellular senescence is a state of stable cell arrest
with active metabolism. Similar to apoptosis, senescence can
be a failsafe program against a variety of cellular insults.
In contrast to apoptosis, however, in which the cytotoxic
signals converge to a common mechanism, senescence is
typically a delayed stress response involving multiple eﬀector
mechanisms. Autophagy can delay apoptosis and is induced
during the process of senescence which it facilitates [68].
Apoptosis in PBC has been studied most vigorously as
an eﬀector system of T-cell-mediated cell injury. Apoptosis
of BECs and the altered expression of apoptosis-related
molecules have been reported in bile duct lesion [69, 70],
but immune-mediated injuries of BECs have not been fully
clariﬁed. Unique properties of apoptosis in BECs may play
a role in the immune tolerance breakdown [4, 21–23]. In
addition, ourrecentstudiesdisclosedthatcellularsenescence
and autophagy are involved in bile duct lesions in PBC [24–
28]. These novel cellular processes, autophagy and cellular
senescence, may be related to the immunopathology of BECs
t o g e t h e rw i t hA M A si nP B C .
6.1. Apoptosis and PBC
6.1.1. Molecules Related to Apoptosis. There is evidence that
BECs undergo apoptosis in PBC for a study using in situ
nick-end labeling methods to detect the DNA fragmentation
of apoptosis, although the mechanisms responsible are
not clear [69]. However, it appears diﬃcult to distinguish
apoptosis, and necrotic DNA fragmentation did not neces-
sarily occur. Studies have shown the increased expression
of perforin and granzymes in PBC, and Fas (CD95) is
upregulated on the biliary epithelial cell membrane, so it is
possible that both of these pathways are involved [70].
6.1.2. Unique Features of BECs during Apoptosis. PBC bile
duct cells manifest unique features during apoptosis while
coculture experiments do not support a direct role for
these cells in determining their immune-mediated injury.
Odin et al. ﬁrst demonstrated that PDC-E2 remains intact
and retains its immunogenicity in BECs during apoptosis
because of a cell-speciﬁc lack of glutathionylation of BECs
[23]. The intact PDC-E2 in apoptotic fragments could be
taken up by local antigen-presenting cells and transferred
to regional lymph nodes for the priming of cognate T
cells. Lleo et al. reported that BECs translocate intact
PDC-E2 immunologically to apoptotic bodies, creating an
apotope [21, 22]. They also demonstrated inﬂammatory
cytokine production in the presence of a unique triad of
BEC apotopes, and macrophages from patients with PBC
and AMAs [21]. These studies may provide insights into
w h ya u t o i m m u n ed a m a g ei sp r i m a r i l yc o n ﬁ n e dt oB E C si n
small bile ducts [21]. Allina et al. reported that apoptotic
BECs were phagocytosed by BECs in PBC, and this may
consequently provide an exogenous source of autoantigens
in BECs [40].Hepatitis Research and Treatment 5
6.2. Autophagy and PBC. Autophagy is an evolutionarily
conserved process that results from various cellular stresses
such as nutrient damage and activation of the endoplasmic
reticulum stress pathway [65–67]. Autophagy can enable
adaptation to stress through the degradation of cellular
proteins and organelles to suppress damage, maintain
metabolism, and promote cellular viability and ﬁtness [65–
67]. Three types of autophagy— macroautophagy, microau-
tophagy, and chaperone-mediated autophagy— have been
classiﬁed and macroautophagy is the major type [65–67]. It
is now clear that macroautophagy (hereafter referred to as
autophagy) is important for many physiological and patho-
logical processes. During stresses such as nutrient depriva-
tion or mitochondrial damage, autophagy is activated and
organelles are sequestered in autophagosomes and digested
byfusionwithlysosomestoeithergenerateenergyorcontain
collateraldamagesuchasinductionofapoptosisduetodam-
aged mitochondria. This evolutionarily conserved process is
characterized by the formation of double-membrane cytoso-
lic vesicles, autophagosomes, which sequester the cytoplas-
mic content and deliver it to lysosomes [71, 72]. Autophagy
is often associated with acute metabolic changes and rapid
protein replacement. Microtubule-associated protein-light
chain 3β (LC3), a homologue of autophagy-related protein
8 (Apg8p), which is essential for autophagy and associated
withautophagosomemembranesafterprocessing,isawidely
used marker of autophagy [68, 73]. Recent studies disclosed
that autophagy is induced during the process of senescence
which it facilitates [68].
Autophagy may be a novel player in autoimmunity, that
is, by MHC-class II presentation of cytosolic antigens and
control of T-cell homeostasis [41, 74, 75]. Autophagy-related
processingofself-proteinsprovidesasourceofimmunostim-
ulatory molecules and autoantigens [41, 74, 75].
6.2.1. Biliary Epithelial Autophagy in PBC. In our recent
study, autophagy was speciﬁcally upregulated in damaged
small bile ducts along with cellular senescence in PBC [28]
(Figure 2). A representative autophagy marker, LC3, was
characteristically expressed in cytoplasmic vesicles in the
damaged small bile ducts in PBC [28]. Senescent markers
p21WAF1/Cip1 and p16INK4a were coexpressed with autophagic
marker LC3 in damaged bile ducts in PBC [28]. The
inhibition of autophagy suppressed cellular senescence in
cultured cells [28]. These ﬁndings suggest that autophagy
may mediate the process of biliary epithelial senescence
and be involved in the pathogenesis of bile duct lesions
in PBC. A major question related to this study is how
autophagy/cellular senescence is related to the autoimmune
etiology proposed for PBC. Autophagy of BECs may play
a role in the immune tolerance breakdown of autoantigen:
PDC-E2 in PBC, although this is only speculative at this
moment. This important issue remains to be fully clariﬁed.
6.3. Cellular Senescence in PBC. Cellular senescence is
deﬁnedasaconditioninwhichacellnolongerhastheability
to proliferate. Senescent cells are irreversibly arrested at the
G1 phase of the cell cycle and do not respond to various
Figure 2: Biliary epithelial autophagy in PBC. The expression of
autophagy marker LC3 was detected in intracytoplasmic vesicles
(arrows) in BECs involved in damaged small bile ducts in PBC.
Immunostaining for LC3. Original magniﬁcation, ×400 (inset,
×1000).
external stimuli but remain metabolically active. Senescent
cells display several characteristics, including histological
changes in vitro and in vivo [76, 77], shortened telom-
eres, increased expression of p16INK4 and p21WAF1/Cip,a n d
increased activity of senescence-associated β-galactosidase
(SA-β-gal)[78]. Cellular senescence can be triggered by mul-
tiple mechanisms, including telomere shortening, epigenetic
derepression of the INK4a/ARF locus, and DNA damage
[79]. Cellular senescence imposes a potent barrier to tumori-
genesis and contributes to the cytotoxicity of certain anti-
cancer agents [79, 80]. Interestingly, senescent cells have also
been observed in certain aged or damaged tissues and have
beensuggestedtolimitcelldepletionandthedeclineoftissue
regeneration capacity with age [79]. Senescence may also act
as part of a homeostatic mechanism to limit wound-healing
responses following tissue damage [81]. Recent progress in
the ﬁeld of hepatology has disclosed that cellular senescence
is involved in the pathophysiology of various chronic liver
diseases [24–26, 81–84] and hepatocarcinogenesis [85, 86].
6.3.1. Biliary Epithelial Senescence in PBC. We have reported
the cellular senescence of BECs with shortened telomeres,
the expression of SA-β-gal, and the augmented expression
of p16INK4a and p21WAF1/Cip in damaged small bile ducts
in PBC (Figure 3) and suggested that cellular senescence
may be involved in the pathogenesis of progressive bile duct
loss in PBC [24, 27]. The possible association of oxidative
stress and decreased expression of polycomb group protein
Bmi1 was suggested to be involved in the pathogenesis of
cellular senescence in PBC [24–26]. Similar biliary epithelial
senescence was reported in chronic liver allograft rejection,
in which intrahepatic bile ducts are diminished [82].
There are many unanswered questions to clarify how
senescent BECs relate to bile duct loss (ductopenia) in PBC.
Senescent cells are known to contribute to impaired tissue
integrity and persistent inﬂammation [87]. When cellular
senescence occurs in injured BECs, these senescent cells6 Hepatitis Research and Treatment
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Figure 3: Biliary epithelial senescence in PBC. BECs in small bile ducts involved in CNSDC show histological features of senescence, such
as cytoplasmic eosinophilia, cellular and nuclear enlargement, and uneven nuclear spacing (a). SA-β-gal activity is detected in BECs in PBC
(b). Senescent markers, p21WAF1/Cip1 and p16INK4a, were expressed in BECs in damaged small bile ducts in PBC (c, d). Immunostaining for
p21WAF1/Cip1 and p16INK4a. Original magniﬁcation, ×400.
are thought to remain in situ and not to be replaced by
normal cells, although nonsenescent BECs proliferate in
response to injury [88]. It is conceivable that impaired
replacement and nonproliferative properties of senescent
BECs make them prone to further injuries, accentuating
inﬂammation by SASP, which is likely to be followed by bile
duct loss in PBC. The fate of senescent BECs remains to be
clariﬁed: whether senescent BECs are removed by apoptosis,
anoikis, or necrosis. Our previous studies reported that
cellular senescence is frequently seen in bile ductular cells
in a ductular reaction, which are thought to harbor hepatic
stem/progenitor cells in PBC [24, 27]. This phenomenon
may also be related to the impaired regeneration of BECs in
small bile ducts in PBC.
6.3.2. Senescence-Associated Secretory Phenotypes (SASPs).
Recent studies suggest that senescent cells play an important
role in modulating the microenvironment by secreting
biological active molecules, such as cytokines (IL-6, IL-
1, and so on), chemokines (CXCL8/IL-8, CCL2/monocyte
chemotacticprotein-1(MCP)-1),andsoon),growthfactors,
and proﬁbrogenic factors [89–93]. In fact, studies in humans
withbiliary disordersand inanimalmodels of biliaryﬁbrosis
have shown that the ductal epithelium can express a number
of proﬁbrogenic and chemotactic proteins (e.g., IL-1, IL-
6, CXCL8/IL-8, and CCL2/MCP-1), the latter capable of
attracting and activating cells of both inﬂammatory and
stellate cell lineage [39, 55, 56, 94]. These cytokines and
chemokines may belong to SASPs [89–93].
6.3.3. SASPs in PBC. Previous reports, including those
from our group, have reported the upregulation of several
cytokines and chemokines in damaged bile ducts in PBC
as described above [39, 47, 56], and recent studies have
disclosed that most of these factors are known to belong to
SASPs [89–93]. Our recent study disclosed the involvement
of senescent BECs in modulation of the inﬂammatory
microenvironment around aﬀected small bile ducts in PBC
[29]. We examined the chemokine proﬁles in cultured
senescent BECs and the chemotactic capacity and also the
correlation between the expression of senescent features
and chemokine proﬁles in human PBC livers by immuno-
histochemistry [29]. Senescent BECs induced by various
stresses expressed a signiﬁcantly higher level of chemokines.Hepatitis Research and Treatment 7
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Figure 4: Possible regulation of microenvironment by senescent
BECs expressing SASPs such as chemokines and cytokines in PBC.
Senescent BECs may participate in modulation of the inﬂammatory
microenvironment by recruiting monocytes and possibly other
typesofinﬂammatorycells,inductionofsenescenceinsurrounding
cells, and progression of ﬁbrosis via SASP.
Senescent BECs signiﬁcantly facilitated the migration of
RAW264.7 cells, and neutralizing antibodies against CCL2
and CX3CX1 partially blocked the migration induced by
senescent BECs. The expression of CCL2 and CX3CL1 was
signiﬁcantly higher in BECs in inﬂamed and damaged small
bile ducts in PBC than in noninﬂamed bile ducts and control
livers. The expression of CCL2 and CX3CL1 was colocalized
with the expression of senescent markers. These ﬁndings
suggest that senescent BECs may participate in modulation
of the inﬂammatory microenvironment by recruiting mono-
cytes and possibly other types of inﬂammatory cells via SASP
(Figure 4).
Very little is known about the mechanism which initiates
and maintains SASPs, including chemokines [79, 89–91].
Since several types of cellular stress, such as oxidative
stress, DNA damage by etoposide, and serum deprivation,
induced SASPs in senescent BECs in the present study,
and it is plausible that these stresses may induce SASPs
via a common mechanism in the senescent state. Similarly,
SASPs in senescent BECs in PBC may contribute to the
activation of the innate immune system around the injured
bileducts.Upregulationofseveralcytokinesandchemokines
has been reported in damaged bile ducts in PBC [39,
47, 56]. This study raised the possibility that most of
such cytokine and chemokine proﬁles may be included in
SASPs. Senescence is both regulated by and regulates the
extracellular environment.
7. Summary
PBC, like most polygenic autoimmune diseases, clearly
belongs to the “complex disease” category that is attributable
to the combined eﬀects of multiple environmental and
behavioral inﬂuences, genetic elements, and perhaps chance.
Mitochondrial autoantigens and B-cell and T-cell autoepi-
t o p e sh a v eb e e nw e l lc h a r a c t e r i z e di nP B C ;h o w e v e r ,t h e
etiologyandtherelationbetweenAMAsandbileductlesions
remain to be determined. We emphasized the features of
BECs in bile duct lesions in PBC, in particular, the unique
feature of apoptotic BECs which retain immunologically
intact PDC-E2 and two novel cellular processes: autophagy
and cellular senescence. Autophagy may be a promising
cellular mechanism involved in the autoimmune mechanism
together with apoptosis. Cellular senescence may be related
to the immunopathology of BECs by the expression of SASPs
in PBC. Further studies are warranted to completely disclose
the pathogenesis of PBC.
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